

FORM PTO-1390
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

6627-PA9025

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/830,779

INTERNATIONAL APPLICATION NO.
PCT/US99/25692INTERNATIONAL FILING DATE
2 NOVEMBER 1999PRIORITY DATE CLAIMED
2 NOVEMBER 1998TITLE OF INVENTION A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE
AND HEART FAILURE

APPLICANT(S) FOR DO/EO/US Kenneth CHIEN, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:-

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371. #3
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Response to Notification to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures directing the entry of the Sequence Listing into the specification (2 pgs); An initial computer readable form (CRF) of the Sequence Listing (1- 3.5 in. diskette); An initial paper copy of the Sequence Listing (9 pgs); Statement Under 37 CFR 1.82(f) and (g) (1 pg); Copy of the Notification to Comply (1 pg); Return Postcard.

IN THE UNITED STATES ELECTED OFFICE (EO/US)

PTO/PCT Rec'd 04 AUG 2001

International Application No.:

PCT/US99/25692

International Filing Date:

2 November 1999

Title:

A METHOD FOR INHIBITION OF PHOSPHOLAMBAN
ACTIVITY FOR THE TREATMENT OF
CARDIAC DISEASE AND HEART FAILURE

Applicant:

The Regents of the University of California

U.S. Serial No.:

09/830,779

RESPONSE TO NOTIFICATION TO COMPLY

Assistant Commissioner for Patents

Box PCT

Washington, D.C. 20231

Attention: EO/US

FEE VALUE	
194 30.00	
2 4070	
194 30.00	

Dear Sir:

In response to the Notification to Comply with Requirements for Patents Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Office on 09 June 2001, enclosed are the following:

"Express Mail" Mailing Label No. EL634292879US

Date of Deposit 3 August 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

Jeanne M. Brush

(Name)

Jeanne M. Brush

(Signature)


1. An initial computer readable form (CRF) of the Sequence Listing (1-3.5 in. diskette;
2. An initial paper copy of the Sequence Listing (9 pages);
3. A statement under 1.82(f) and (g) (1 page);
4. A copy of the Notice to Comply and
5. A return postcard.

As the response to the notice to comply was filed within the two month period, it is believed that there is no fee due. However, the Commissioner is authorized to charge account 02-4070 referencing case number 6627-PA9025 if a fee is required.

Respectfully submitted,

Dated: 3 August 2001

By:



Colleen J. McKiernan
Agent for Applicant
Reg. No. P-48,570

BROWN MARTIN HALLER & McCLAIN LLP
1660 Union Street
San Diego, California 92101

Telephone: (619) 238-0999
Facsimile: (619) 238-0062

Docket No.: 6627-PA9025